ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
부종 임상시험 시장 규모는 최근 수년간 강력하게 성장하고 있습니다. 2024년 11억 3,000만 달러에서 2025년에는 12억 3,000만 달러에 달하고, CAGR 8.9%로 확대될 전망입니다. 실적기간 내 성장은 부종의 유병률 증가, 만성질환의 부담 증가, 헬스케어 의식과 진단 증가, 헬스케어 인프라 확대, 노인 인구 증가, 공적 및 민간 자금 증가 등에 의해 발생하였습니다.
부종 임상시험 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.6%로 17억 1,000만 달러로 성장할 전망입니다. 예측기간에 있어서의 성장의 원동력은 맞춤 의료에 대한 수요 증가, 환자 모집의 다양성에 대한 주목의 고조, 분산형 임상시험이나 가상 임상시험의 성장, 정부 지원 프로그램의 확대, 세계적인 제약 기업의 투자 확대 등입니다. 예측 기간의 주요 동향으로는 원격 모니터링 기술 진보, 디지털 바이오마커 혁신, 인공지능 분석 개발, 3차원 영상 진보, 맞춤 치료 연구, 임상시험과 원격 의료의 통합 등이 있습니다.
부종 임상시험 시장의 확대는 생활습관병의 이환율 증가가 크게 기여할 것으로 예측됩니다. 이러한 질병은 운동 부족, 영양 불균형, 약물 사용과 같은 일상적인 습관과 행동의 결과로 발생합니다. 이러한 질병 증가는 주로 건강에 해로운 다이어트 패턴으로 인해 발생하며 가공 식품과 고칼로리 식품의 광범위한 소비는 비만, 당뇨병 및 심혈관 합병증을 유발합니다. 부종 임상시험은 이러한 만성 건강 문제와 관련된 체액 저류의 치료법을 개발하고 평가함으로써 이러한 질병에 대처하는 데 중요한 역할을 합니다. 예를 들어 2024년 3월 영국 정부 기관인 건강격차개선사무국은 2022년 3월부터 2023년 3월에 걸쳐 1형 당뇨병 환자 중 권장되는 8가지 케어 프로세스를 모두 받은 사람의 비율이 22% 증가했으며 2형 당뇨병 환자에서는 21% 증가했다고 보고했습니다. 게다가 HbA1c의 목표치를 달성한 사람의 비율은 37.9%로 상승해 전국 당뇨병 조사에서 역대 최고를 기록했습니다. 그 결과, 생활습관병 유병률 증가가 부종 임상시험 시장의 성장을 이끌고 있습니다.
부종 임상시험 시장의 진출기업은 만성 부종과 관련된 안과 질환을 관리하기 위한 치료 효과와 환자의 충실도를 높이기 위해 리필식 안구 임플란트와 같은 고급 솔루션의 개발을 선호합니다. 리필식 안구 임플란트는 눈에 장착하는 의료기기이며 장기간 지속적으로 약물을 투여하고 제거하거나 교체하지 않고 재충전할 수 있기 때문에 황반 부종과 같은 만성 질환에 유리한 장기 치료 옵션입니다. 예를 들어 2025년 2월 스위스에 본사를 두고 있는 제약회사인 Roche Holding AG는 미국 식품의약국에서 당뇨병 황반부종과 당뇨병 망막증에 대한 최초의 유일한 지속 약물 전달 시스템인 서스비모의 승인을 취득했습니다. 이 병들은 당뇨병 환자의 시력 저하의 주요 원인입니다. 서스비모는 연간 치료 횟수를 크게 줄임으로써 빈번한 안과 주사를 대체하는 치료법을 제공합니다. 이 기술 혁신은 치료의 충실도를 개선하고 환자의 부담을 줄임으로써 안과 의료에서 큰 진전을 불러일으킵니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 부종 임상시험 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 부종 임상시험 시장 : 성장률 분석
세계의 부종 임상시험 시장 실적 : 규모와 성장(2019-2024년)
세계의 부종 임상시험 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 부종 임상시험 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 부종 임상시험 시장 : 단계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
1상
2상
3상
4상
세계의 부종 임상시험 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
말초성 부종
폐수종
뇌부종
네프로제 증후군 부종
세계의 부종 임상시험 시장 : 시험 디자인별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
인터벤션
관찰 연구
확장 액세스
세계의 부종 임상시험 시장 : 참가자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소아
성인
노인
세계의 부종 임상시험 시장 : 최종사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제약기업
연구기관
수탁연구기관(CRO)
학술연구센터
세계의 부종 임상시험 시장 세분화 : 1상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일 용량상승 투여
다중 용량상승 투여
세계의 부종 임상시험 시장 세분화 : 2상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
개념 증명
2b상 용량 최적화
세계의 부종 임상시험 시장 세분화 : 3상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
피보탈 효능 시험
비교 시험
세계의 부종 임상시험 시장 세분화 : 4상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
시판 후 조사
장기 안전성 시험
제7장 지역별/국가별 분석
세계의 부종 임상시험 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 부종 임상시험 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
부종 임상시험 시장 : 경쟁 구도
부종 임상시험 시장 : 기업 프로파일
Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis International AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
CSL Limited
Regeneron Pharmaceuticals Inc.
Boehringer Ingelheim International GmbH
Genentech Inc.
Ionis Pharmaceuticals Inc.
ANI Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc.
Tactile Medical
REGENXBIO Inc.
Koya Medical Inc.
KalVista Pharmaceuticals Inc.
Kodiak Sciences Inc.
Pharvaris BV
Oxurion NV
Outlook Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
부종 임상시험 시장(2029년) : 새로운 기회를 제공하는 국가
부종 임상시험 시장(2029년) : 새로운 기회를 제공하는 부문
부종 임상시험 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Edema clinical trials are studies conducted to assess the safety, effectiveness, and potential treatments for edema, which is the abnormal accumulation of fluid in body tissues. These trials evaluate drugs, medical devices, or therapeutic interventions aimed at reducing swelling, improving fluid balance, or addressing underlying conditions such as heart, kidney, or liver disorders.
The primary phase types of edema clinical trials are Phase I, Phase II, Phase III, and Phase IV. Phase I trials represent the initial stage of clinical research, focusing on evaluating the safety, tolerability, and optimal dosage of a new therapy in a small group of participants. These trials cover various types of edema, including peripheral edema, pulmonary edema, cerebral edema, and nephrotic syndrome edema. Study designs include interventional, observational, and expanded access trials. Participants include pediatric, adult, and geriatric populations, and key end-users consist of pharmaceutical companies, research institutions, contract research organizations (CROs), and academic research centers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The edema clinical trials market research report is one of a series of new reports from The Business Research Company that provides edema clinical trials market statistics, including edema clinical trials industry global market size, regional shares, competitors with an edema clinical trials market share, detailed edema clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the edema clinical trials industry. This edema clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The edema clinical trials market size has grown strongly in recent years. It will grow from $1.13 billion in 2024 to $1.23 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period is attributed to the increasing prevalence of edema conditions, rising burden of chronic diseases, growing healthcare awareness and diagnosis, expansion of healthcare infrastructure, increasing geriatric population, and higher public and private funding.
The edema clinical trials market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period is driven by rising demand for personalized medicine, increased focus on patient recruitment diversity, growth of decentralized and virtual clinical trials, expansion of government support programs, and higher investment from global pharmaceutical companies. Key trends in the forecast period include technological advancements in remote monitoring, innovation in digital biomarkers, development of artificial intelligence analytics, progress in three-dimensional imaging, research in personalized therapies, and integration of telemedicine into clinical trials.
The growing incidence of lifestyle-related diseases is expected to contribute significantly to the expansion of the edema clinical trials market. These diseases develop as a result of daily habits and behaviors, including physical inactivity, poor nutrition, and substance use. The rise in such conditions is primarily due to unhealthy dietary patterns, with the widespread consumption of processed and high-calorie foods leading to obesity, diabetes, and cardiovascular complications. Edema clinical trials play a key role in addressing these diseases by developing and evaluating treatments for fluid retention commonly associated with these chronic health issues. For example, in March 2024, the Office for Health Improvement and Disparities, a government department in the United Kingdom, reported that from March 2022 to March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by twenty-two percent, and for those with type 2 diabetes, the increase was twenty-one percent. Additionally, the percentage of individuals achieving target HbA1c levels rose to thirty-seven point nine percent, the highest ever recorded by the National Diabetes Audit. As a result, the growing prevalence of lifestyle-related diseases is supporting the growth of the edema clinical trials market.
Companies involved in the edema clinical trials market are prioritizing the development of advanced solutions such as refillable eye implants to enhance treatment effectiveness and patient adherence for managing chronic edema-related eye disorders. A refillable ocular implant is a medical device placed in the eye that delivers medication continuously over time and can be refilled without removal or replacement, making it a long-term treatment option for chronic conditions such as macular edema. For example, in February 2025, Roche Holding AG, a pharmaceutical company based in Switzerland, received approval from the United States Food and Drug Administration for Susvimo, the first and only continuous medication delivery system for diabetic macular edema and diabetic retinopathy. These are leading causes of vision loss in individuals with diabetes. Susvimo provides an alternative to frequent eye injections by significantly reducing the number of treatments required annually. This innovation represents a major step forward in eye care by improving treatment adherence and lowering the burden on patients, which may lead to better long-term outcomes for those affected by these chronic eye conditions.
In September 2025, Alcon Inc., an eye care device company based in Switzerland, acquired LumiThera Inc. for an undisclosed amount. Through this acquisition, Alcon aims to expand the availability of LumiThera's Valeda photobiomodulation device, which is used for the treatment of early and intermediate stages of dry age-related macular degeneration. This move enhances Alcon's retinal treatment offerings by adding clinic-based, noninvasive therapies designed to help a large number of patients improve their vision. LumiThera Inc. is a medical device company based in the United States that conducts edema clinical trials.
Major players in the edema clinical trials market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, CSL Limited, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Ionis Pharmaceuticals Inc., ANI Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Tactile Medical, REGENXBIO Inc., Koya Medical Inc., KalVista Pharmaceuticals Inc., Kodiak Sciences Inc., Pharvaris B.V., Oxurion NV, Outlook Therapeutics Inc., Adverum Biotechnologies Inc., Oculis Holding AG.
North America was the largest region in the edema clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in edema clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the edema clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The edema clinical trials market includes revenues earned by entities by providing services such as patient recruitment and screening, safety and adverse event reporting, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Edema Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on edema clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for edema clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The edema clinical trials market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Phase: Phase I; Phase II; Phase III; Phase IV
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Edema Clinical Trials Market Characteristics
3. Edema Clinical Trials Market Trends And Strategies
4. Edema Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Edema Clinical Trials Growth Analysis And Strategic Analysis Framework
5.1. Global Edema Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Edema Clinical Trials Market Growth Rate Analysis
5.4. Global Edema Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Edema Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Edema Clinical Trials Total Addressable Market (TAM)
6. Edema Clinical Trials Market Segmentation
6.1. Global Edema Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phase I
Phase II
Phase III
Phase IV
6.2. Global Edema Clinical Trials Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peripheral Edema
Pulmonary Edema
Cerebral Edema
Nephrotic Syndrome Edema
6.3. Global Edema Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interventional
Observational
Expanded Access
6.4. Global Edema Clinical Trials Market, Segmentation By Participant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatrics
Adults
Geriatrics
6.5. Global Edema Clinical Trials Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Research Institutions
Contract Research Organizations (CROs)
Academic Research Centers
6.6. Global Edema Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single Ascending Dose
Multiple Ascending Dose
6.7. Global Edema Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phase IIa Proof of Concept
Phase IIb Dose Optimization
6.8. Global Edema Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pivotal Efficacy Trials
Comparative Trials
6.9. Global Edema Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Post-Marketing Surveillance
Long-Term Safety Studies
7. Edema Clinical Trials Market Regional And Country Analysis
7.1. Global Edema Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Edema Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
